Opendata, web and dolomites

ASPIVIX

Vacuum Medical Device for Safe and Gentle Cervix Grasping Gynecological Applications

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ASPIVIX project word cloud

Explore the words cloud of the ASPIVIX project. It provides you a very rough idea of what is the project "ASPIVIX" about.

intervention    curettage    billions    markets    care    economic    unintended    29    shorten    gynecologist    generate    indications    pain    north    besides    roi    cross    valued    84    practices    cavity    trigger    pulling    uterine    traumatic    forceps    unchanged    uterus    euros    yearly    fulfill    representing    grow    inside    tenaculum    featured    for    market    sales    revenues    contamination    instead    procedure    poor    patented    prevents    iucd    considering    contraceptive    pregnancies    disruptive    proved    traction    women    total    exacerbates    female    vaginal    bleeding    disadvantages    6m    cagr2016       return    asian    reduce    cumulative    replace    refrain       reduces    units    lesions    risk    sized    social    gynecologists    thanks    adoption    gynecological    single    10    demand    aspivix    85    american    patients    benefit    projected    device    investment    infection    cervix    64    exploration    350m    painful    28    firm    intended    insertions    physician    mills    eradicates    gentle    worldwide    2021    22m    nearly    invested       grasping   

Project "ASPIVIX" data sheet

The following table provides information about the project.

Coordinator
ASPIVIX SA 

Organization address
address: CHEMIN DE RENENS 2 BIS
city: LAUSANNE
postcode: 1004
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Project website http://www.aspivix.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-05-01   to  2018-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ASPIVIX SA CH (LAUSANNE) coordinator 50˙000.00

Map

 Project objective

For years, gynecologist practices related to Intra-Uterine Contraceptive Device (IUCD) insertions, curettage and several other common indications, have featured poor care and low attention to female patients.
The use of the Tenaculum, grasping and pulling on the cervix, inside the vaginal cavity, proved to be painful and traumatic for 84% of the women, and eventually to trigger lesions and bleeding in 29% of the patients, as well as cross-contamination in 5-10% of the women. These disadvantages refrain the use of IUCD contraceptive which exacerbates the unintended pregnancies, sized yearly in 85 mills and representing billions of euros in social costs worldwide. In response, we have developed Aspivix, a new disruptive gynecological device that reduces the pain and eradicates the bleeding during the exploration procedure. Our patented device will replace the Tenaculum forceps, unchanged for over 100 years, to provide gynecologists an easy-to-use device where gentle and firm cervix uterus grasping and traction is needed. Thus, our device will facilitate the adoption of IUCD, which could avoid up to 8% of unintended pregnancies and reduce derived social costs. Besides, Aspivix is intended for a single use which prevents the risk of contamination and cross-infection. Overall, Aspivix has the potential to shorten the intervention procedure (2 steps instead 7), which will represent for the physician a 28% economic benefit. As result, Aspivix will fulfill the needs of more than 64 M of women worldwide/year, a market that is projected to grow at a CAGR2016-2021 of ~6.5% due to the high demand of IUCD insertions and is valued in more than €350M. In this way, thanks to the sales of 22M units in the European, Asian and North American Markets after 5-years, Aspivix will generate cumulative revenues of nearly €80 M and, considering the total investment of €3.6M, a return of investment (ROI) of €8.3 per euro invested.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ASPIVIX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ASPIVIX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Proteus 25 (2018)

Developing the world’s first food wrapping machine with organic film

Read More  

ALR4000 (2019)

Automated LCD Recycling series 4000

Read More  

Preemie (2019)

Personalised nutrition of low-birth-weight infants

Read More